TY - JOUR
T1 - Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study
AU - van Capelleveen, Julian C.
AU - Lee, Sang-Rok
AU - Verbeek, Rutger
AU - Kastelein, John J. P.
AU - Wareham, Nicholas J.
AU - Stroes, Erik S. G.
AU - Hovingh, G. Kees
AU - Khaw, Kay-Tee
AU - Boekholdt, S. Matthijs
AU - Witztum, Joseph L.
AU - Tsimikas, Sotirios
PY - 2018
Y1 - 2018
N2 - Background: Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk. Objective: To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events. Methods: apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up. These measures were correlated with a variety of lipid measurements and the presence of CAD. The indices of “total apoCIII-apoB” and “total apoCIII-apoAI” were derived by multiplying plasma apoB and apoAI, respectively. Results: apoCIII-apoB (P =.001), apoCIII-Lp(a) (P <.001), apoCIII-apoAI (P =.005) were higher in cases vs controls; tended to correlate positively with body mass index, hsCRP, apoC-III, low-density lipoprotein (LDL) cholesterol, triglycerides, remnant cholesterol, very low density lipoprotein, LDL and high-density lipoprotein particle number and very low density lipoprotein size; but negatively with LDL and high-density lipoprotein particle size (P <.001 for all). apoCIII-apoB, apoCIII-apoAI, apoCIII-Lp(a), total apoCIII-Lp(a), and total apoCIII-apoB were predictors of CAD after adjustment of age, sex, body mass index, smoking, diabetes, hypertensive and lipid-lowering drug use, but they lost their significance after further adjustment of lipid and lipoprotein variables. Conclusions: This study suggests that enzyme-linked immunoassay–measured lipoprotein-associated apoC-III markers reflect atherogenic lipid particles but do not independently predict risk of CAD events.
AB - Background: Plasma apolipoprotein C-III (apoC-III) levels are associated with coronary artery disease (CAD) risk. Objective: To assess whether lipoprotein-associated apoC-III levels predict risk of CAD events. Methods: apoC-III associated with apoB, apoAI, and Lp(a) (apoCIII-apoB, apoCIII-apoAI, and apoCIII-Lp(a), respectively) were measured using high-throughput chemiluminescent enzyme-linked immunoassays in 2711 subjects (1879 controls and 832 cases with CAD) in the European Prospective Investigation into Cancer and Nutrition-Norfolk prospective population study with 7.4 years of follow-up. These measures were correlated with a variety of lipid measurements and the presence of CAD. The indices of “total apoCIII-apoB” and “total apoCIII-apoAI” were derived by multiplying plasma apoB and apoAI, respectively. Results: apoCIII-apoB (P =.001), apoCIII-Lp(a) (P <.001), apoCIII-apoAI (P =.005) were higher in cases vs controls; tended to correlate positively with body mass index, hsCRP, apoC-III, low-density lipoprotein (LDL) cholesterol, triglycerides, remnant cholesterol, very low density lipoprotein, LDL and high-density lipoprotein particle number and very low density lipoprotein size; but negatively with LDL and high-density lipoprotein particle size (P <.001 for all). apoCIII-apoB, apoCIII-apoAI, apoCIII-Lp(a), total apoCIII-Lp(a), and total apoCIII-apoB were predictors of CAD after adjustment of age, sex, body mass index, smoking, diabetes, hypertensive and lipid-lowering drug use, but they lost their significance after further adjustment of lipid and lipoprotein variables. Conclusions: This study suggests that enzyme-linked immunoassay–measured lipoprotein-associated apoC-III markers reflect atherogenic lipid particles but do not independently predict risk of CAD events.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053696465&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30249512
U2 - https://doi.org/10.1016/j.jacl.2018.08.010
DO - https://doi.org/10.1016/j.jacl.2018.08.010
M3 - Article
C2 - 30249512
SN - 1933-2874
VL - 12
SP - 1493-1501.e11
JO - Journal of clinical lipidology
JF - Journal of clinical lipidology
IS - 6
ER -